ERBB2 and ductal breast carcinoma in situ: Interestingly, DCIS has HER2 amplification with higher frequency than invasive tumors and this HER2-positive DCIS is often associated with comedo DCIS which carries twice the risk of local recurrence as compared to non-comedo DCIS [29, 30].